Last reviewed 2026-04-20 · How we verify

Flogene (FENTIAZAC)

Phase 2 active Small molecule

Flogene (generic name: FENTIAZAC) is a fentiazac drug. It is currently in Phase 2 development for Pain.

Flogene works by blocking the action of prostaglandin D2, a chemical that transmits pain signals to the brain.

Flogene (Fentiazac) is a small molecule drug that targets the Prostaglandin D2 receptor 2. It is classified as a fentiazac and is used to treat pain. The commercial status of Flogene is currently unknown, and it is not clear if it is patented or available as a generic medication. As a fentiazac, Flogene works by interacting with the Prostaglandin D2 receptor 2, which plays a role in pain perception.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENTIAZAC
Drug class	fentiazac
Target	Prostaglandin D2 receptor 2
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Think of prostaglandin D2 like a messenger that tells your brain that you're in pain. When Flogene blocks this messenger, it helps to reduce the pain signal that reaches your brain, providing relief from discomfort.

Approved indications

Pain

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Flogene CI brief — competitive landscape report
Flogene updates RSS · CI watch RSS

Frequently asked questions about Flogene

What is Flogene?

Flogene (FENTIAZAC) is a fentiazac drug, indicated for Pain.

How does Flogene work?

Flogene works by blocking the action of prostaglandin D2, a chemical that transmits pain signals to the brain.

What is Flogene used for?

Flogene is indicated for Pain.

What is the generic name of Flogene?

FENTIAZAC is the generic (nonproprietary) name of Flogene.

What drug class is Flogene in?

Flogene belongs to the fentiazac class. See all fentiazac drugs at /class/fentiazac.

What development phase is Flogene in?

Flogene is in Phase 2.

What does Flogene target?

Flogene targets Prostaglandin D2 receptor 2 and is a fentiazac.

Drug class: All fentiazac drugs
Target: All drugs targeting Prostaglandin D2 receptor 2
Therapeutic area: All drugs in Pain
Indication: Drugs for Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing